ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
July 12, 2018Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients with a BRCA mutation as well as those without a BRCA mutation, has been accepted onto the Cancer Drugs Fund (CDF). -
Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women with Recurrent Ovarian Cancer
May 30, 2018today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive
Pharma Sources Insight January 2025
